Business Context and Reporting Period
Company: Alcon, Inc. (Swiss corporation, majority-owned subsidiary of Nestlé S.A.)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Three and six months ended June 30, 2009
Filing Date: July 23, 2009
Business Overview: Alcon operates globally in the ophthalmic market through two segments: Alcon United States and Alcon International. Product categories include pharmaceuticals, surgical equipment/devices, and consumer eye care.
Key Financial Metrics
| Metric (in millions) | 3 Months Ended June 30, 2009 |
3 Months Ended June 30, 2008 |
6 Months Ended June 30, 2009 |
6 Months Ended June 30, 2008 |
|---|---|---|---|---|
| Sales | $1,677 | $1,736 | $3,170 | $3,272 |
| Gross Profit | $1,262 | $1,321 | $2,401 | $2,459 |
| Gross Margin % | 75.3% | 76.1% | 75.7% | 75.2% |
| Operating Income | $632 | $646 | $1,146 | $1,146 |
| Net Earnings | $582 | $567 | $1,034 | $996 |
| Diluted EPS | $1.94 | $1.88 | $3.44 | $3.30 |
| Operating Cash Flow | N/A | N/A | $1,115 | $1,072 |
Liquidity and Debt (as of June 30, 2009)
- Cash and Cash Equivalents: $2,260 million
- Short-term Investments: $426 million
- Short-term Borrowings: $883 million
- Long-term Debt: $57 million (net of current maturities)
- Total Shareholders' Equity: $4,780 million
Material Changes vs. Prior Period
- Sales Decline: Global sales decreased 3.4% (Q3) and 3.1% (YTD) compared to the prior year. Unfavorable foreign exchange rates negatively impacted reported sales by 6.7% (Q3) and 7.2% (YTD). On a constant currency basis, sales grew 3.3% (Q3) and 4.1% (YTD), driven by volume growth.
- Profitability: Net earnings increased 2.6% (Q3) and 3.8% (YTD) despite lower sales, primarily due to reduced operating expenses and lower effective tax rates (10.6% in Q3 2009 vs. 12.8% in Q3 2008).
- Product Mix Impact: Sales of TobraDex® declined significantly (60.1% in Q3) due to generic competition following patent expiration. Conversely, glaucoma products (TRAVATAN® family) grew 15.4% (Q3) and 17.0% (YTD).
- Cost Management: Selling, general, and administrative (SG&A) expenses decreased 11.2% (Q3) and 7.0% (YTD), aided by workforce reductions (approx. 260 positions) and lower share-based compensation.
Guidance, Outlook, and Risks
Management Commentary
- Outlook: Management expects generic competition to TobraDex® to continue impacting sales and profits throughout 2009. However, growth in glaucoma products and emerging markets is offsetting these declines.
- Capital Allocation: The company declared a dividend of approximately $3.50 per share ($1,048 million total) in May 2009. Share repurchases under open market programs were halted in December 2008 following the Nestlé-Novartis agreement, though shares are still acquired to cover employee tax withholdings.
- Investment Strategy: The company is liquidating hedge fund and real estate investment trust holdings to reduce portfolio volatility, reinvesting proceeds into cash and fixed-income securities.
Risks and Contingencies
- Patent Litigation: Alcon is engaged in multiple patent infringement lawsuits against generic manufacturers (Teva, Apotex, Barr, Sandoz, Par) regarding key products including Vigamox®, Patanol®, Pataday®, and TRAVATAN®. Adverse rulings could allow generic entry as early as 2010-2014, significantly impacting future sales.
- Antitrust Litigation: Synergetics USA, Inc. filed an antitrust lawsuit alleging monopoly power in the vitreoretinal surgical equipment market. The company believes the claims are without merit.
- Foreign Exchange: Significant exposure to currency fluctuations, particularly the strengthening of the U.S. dollar against foreign currencies, which reduced reported sales.
- Lehman Brothers: The company had $707 million in securities held by Lehman Brothers International (Europe) London. While released, the company reimbursed Nestlé $5.2 million in fees related to the administration, with potential for further adjustments.
Investor Verification Checklist
- Generic Competition Timeline: Verify the status of ongoing patent litigation for TobraDex®, Patanol®, Pataday®, and TRAVATAN® to assess the timing of potential generic entry.
- Constant Currency Growth: Confirm the sustainability of volume growth in emerging markets and the U.S. surgical segment, which is masking the impact of currency headwinds.
- Dividend Sustainability: Review cash flow generation relative to the $1.048 billion dividend payment to ensure liquidity remains robust.
- Investment Portfolio: Monitor the redemption of hedge fund investments and the transition to lower-risk fixed income assets as disclosed in the liquidity section.
- Workforce Reduction Costs: Assess the one-time charges associated with the 260-position reduction and the long-term impact on SG&A margins.